The preferential drug price policy plan that reflects the value of new drugs and the 2nd comprehensive national health insurance plan, which the pharmaceutical and bio-industry are closely eyeing, is expected to be unveiled after the National Assembly audit this year.

The amendment to the Instructions for the Biohealth Innovation Committee under the direct control of the Prime Minister is also expected to be promoted after the National Assembly audit.

The schedules have been delayed compared to the original plan, and the government plans to complete the practicalities after collecting opinions from each sector after the completion of the National Assembly audit.

The result